In the United States, a rare disease is defined as a condition affecting fewer than 200,000 people. In EU countries, any disease affecting fewer than 1 in 2,000 people is considered rare. That number may seem small, but it translates into approximately 246 000 people throughout the EU’s 28 member countries. Most patients suffer from even rarer diseases affecting 1 person in 100,000 or more. There are more than 7,000 rare diseases identified, however, only a fraction of them have approve treatment available. “Orphan drugs” are intended to treat diseases so rare that sponsors are reluctant to develop them under usual marketing conditions. Currently, the regulatory climate is favourable with both FDA and European Medicines Agency, as they offer incentives, tax credits, user waivers and marketing exclusivity. As a result, the number of therapies approved for rare diseases for the past two decades has grown exponentially. Paradigm Global Events is again proud to present its bi-annual Orphan Drugs & Rare Diseases Global Congress 2018 Europe. The conference will provide a unique platform for the convergence of stakeholders in the orphan drugs industry to discuss and network with top tier government, hospitals, pharmaceuticals, biopharmaceuticals, non-profit organisations, orphan drugs developers as well as regional and local manufacturers. We are putting together an agenda that address the driving macroeconomic factors, policies and issues that will steer the development of orphan drugs globally including commercialisation, policies, reimbursement, pricing and more. We look forward to having you be part of the event! The two-day Congress will provide an interactive, cutting edge and comprehensive discussion and networking format led by key experts with intimate knowledge in the industry. Gain practical strategies and best practices on challenges, innovations, technologies and concepts surrounding orphan drugs and rare diseases. Gain Latest Insights On Key Economic Drivers in the Orphan Market: What is Driving the Industry and the Role of Governments? Growing the Market: The Roles of Big Pharmas, Biotechs and Start-Ups Emerging Markets: Challenges and Benefits in Investing in Emerging Markets Europe’s Regulatory Landscape: What Works and What Doesn’t? Medical Devices in the Orphan Realm: Barriers and Opportunities for Medical Devices in Small Populations Strategic Partnerships: What Strategies are available to Ensure Partnership Success Pricing Strategy: How to Price Correctly? Clinical Trials: From Early Drug Development to Patient Recruitment and More

Explore Existing Conferences Across the World or Publish a Conference to Showcase It Globally in VePub.